Hematology

Home
Hematology

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Conditions: Rheumatoid Arthritis; Arthritis, Rheumatoid
Interventions: Biological: GSK3196165; Drug: Tofacitinib 5 mg; Drug: Placebo to GSK3196165; Drug: Placebo to tofacitinib; Drug: Methotrexate; Drug: Folic (or folinic) acid
Sponsors: GlaxoSmithKline; IQVIA
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 10, 2019ClinicalTrials.govComments OffHematologyActive | Arthritis | Efficacy | GSK3196165 | Inadequate | Methotrexate | Moderately | Participants | Placebo | Response | Rheumatoid | Safety | Severely | Tofacitinib | Versus

Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Cord Blood Transplant

Conditions: Acute Myeloid Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Cord Blood Transplant Recipient; Myelodysplastic Syndrome; Myeloproliferative Neoplasm
Intervention: Biological: Recombinant Interleukin-7
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 9, 2019ClinicalTrials.govComments OffHematologyAfter | Blood | Cord | Human | Interleukin7 | Promote | Recombinant | Recovery | Tcell | Transplant

Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

Condition: Breast Cancer
Intervention: Drug: Rucaparib
Sponsor: University of Arizona
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 8, 2019ClinicalTrials.govComments OffHematologyAffect | Breast | Expression | Inhibitor | Negative | Opportunity | PARP | PDL1 | Rucaparib | Trial | Triple | Tumors | Window

Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors

Condition: Prostate Cancer
Intervention: Behavioral: Guided Lifestyle Program Intervention
Sponsors: Medical College of Wisconsin; Loyola University Chicago; Marquette University; University of Illinois at Chicago
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 7, 2019ClinicalTrials.govComments OffHematologyAfricanAmerican | Cancer | Forward | Lifestyle | Moving | Program | Prostate | Survivors

Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: 18F-DCFPyL
Sponsor: National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 6, 2019ClinicalTrials.govComments OffHematologyAntigen | Cancer | High | Imaging | Membrane | Prostate | PSMAbased | Risk | Specific

Phase I Study of HL-085 in Patients With Advanced Solid Tumors

Condition: Solid Tumor, Adult
Intervention: Drug: HL-085
Sponsor: Shanghai Kechow Pharma, Inc.
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 5, 2019ClinicalTrials.govComments OffHematologyAdvanced | HL085 | Patients | Phase | Solid | Study | Tumors

Mechanism of Action Underlying Ketamine s Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

Conditions: Depression; Major Depressive Disorder; Major Depression
Interventions: Drug: Ketamine; Drug: Perampanel; Other: Placebo
Sponsor: National Institute of Mental Health (NIMH)
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 4, 2019ClinicalTrials.govComments OffHematologyAction | AMPA | Antidepressant | Depression | Effects | Ketamine | Major | Mechanism | Patients | Theory | Throughput | TreatmentResistant | Underlying

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

Condition: Arthritis, Rheumatoid
Interventions: Biological: GSK3196165; Drug: Tofacitinib; Drug: Placebo to GSK3196165; Drug: Placebo to Tofacitinib; Drug: csDMARDs
Sponsors: GlaxoSmithKline; IQVIA
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 3, 2019ClinicalTrials.govComments OffHematologyActive | Antirheumatic | Arthritis | Conventional | cs/Biologic | Disease | DMARDs | Drugs | Efficacy | GSK3196165 | Inadequate | Moderately | Modifying | Participants | Placebo | Response | Rheumatoid | Safety | Severely | Synthetic | Tofacitinib | Versus

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Conditions: Chronic Lymphocytic Leukemia; Loss of Chromosome 17p
Interventions: Drug: Ibrutinib; Drug: Venetoclax
Sponsors: Kerry Rogers; National Cancer Institute (NCI); Janssen Research & Development, LLC
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 2, 2019ClinicalTrials.govComments OffHematologyAfter | Chronic | Ibrutinib | Leukemia | Lymphocytic | Patients | Resistance | Treating | Venetoclax

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: BIIB017 (peginterferon beta-1a); Drug: Interferon beta type 1a
Sponsor: Biogen
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 1, 2019ClinicalTrials.govComments OffHematologyBeta1a | BIIB017 | Efficacy | Evaluate | Multiple | Participants | Pediatric | PegInterferon | Relapsingremitting | Safety | Sclerosis | Study | Tolerability | Treatment

1
2
3
…
6
Next »

Free Clinical Trial Updates

#1 Best New Product in 2019

Search For Clinical Trials

CLOSE

Please click to geolocate button to change this value.

Distance (Mile) :

SEARCH RESET

Featured Research Centers